{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T16:00:18Z","timestamp":1760889618110,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III, Spanish Ministry of Economy","award":["PI13\/01474"],"award-info":[{"award-number":["PI13\/01474"]}]},{"name":"Insituto de Salud Carlos III, Spanish Ministry of Economy","award":["REIPI RD12\/0015"],"award-info":[{"award-number":["REIPI RD12\/0015"]}]},{"name":"Bionet Medical S.L."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2647-y","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T12:19:26Z","timestamp":1525263566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-4422","authenticated-orcid":false,"given":"C.","family":"Gudiol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nicolae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Royo-Cebrecos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aguilar-Guisado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mart\u00edn-Gandul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Perayre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Berbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Encuentra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Cisneros-Herreros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"2647_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309\u201317.","journal-title":"Clin Infect Dis"},{"key":"2647_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/08880018.2013.772683","volume":"30","author":"S Celebi","year":"2013","unstructured":"Celebi S, Sezgin ME, Cakir D, Baytan B, Demirkaya M, Sevinir B, et al. Catheter associated bloodstream infections in pediatric hematology-oncology patients. Pediatr Hematol Oncol. 2013;30:187\u201394.","journal-title":"Pediatr Hematol Oncol"},{"key":"2647_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1086\/656594","volume":"31","author":"CJ Crnich","year":"2010","unstructured":"Crnich CJ. Estimating excess length of stay due to central line-associated bloodstream infection: separating the wheat from the chaff. Infect Control Hosp Epidemiol. 2010;31:1115\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2647_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/pbc.24249","volume":"60","author":"J Wolf","year":"2013","unstructured":"Wolf J, Shenep JL, Clifford V, Curtis N, Flynn PM. Ethanol lock therapy in pedi\u00e0tric hematology and oncology. Pediatr Blood Cancer. 2013;60:18\u201325.","journal-title":"Pediatr Blood Cancer"},{"key":"2647_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/pbc.26225","volume":"64","author":"MR Viana Taveira","year":"2017","unstructured":"Viana Taveira MR, Lima LS, de Ara\u00fajo CC, de Mello MJ. Risk factors for central line-associated bloodstream infection in pediatric oncology patients with a totally implantable venous access port: a cohort study. Pediatr Blood Cancer. 2017;64:336\u201342.","journal-title":"Pediatr Blood Cancer"},{"key":"2647_CR6","first-page":"CD003295","volume":"1","author":"MD van de Wetering","year":"2007","unstructured":"van de Wetering MD, van Woensel JB. Prophylactic antibiotics for preventing early central venous catheter Gram-positive infections in oncology patients. Cochrane Database Syst Rev. 2007;1:CD003295.","journal-title":"Cochrane Database Syst Rev"},{"key":"2647_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10096-007-0320-6","volume":"26","author":"I Raad","year":"2007","unstructured":"Raad I, Hachem R, Hanna H, Bahna P, Chatzinikolaou I, Fang X, et al. Sources and outcomes of bloodstream infections in cancer patients: the role of central venous catheters. Eur J Clin Microbiol Infect Dis. 2007;26:549\u201356.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2647_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1586\/14787210.2014.920253","volume":"12","author":"C Gudiol","year":"2014","unstructured":"Gudiol C, Carratal\u00e0 J. Antibiotic resistance in cancer patients. Expert Rev Anti-Infect Ther. 2014;12:1003\u201316.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"2647_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2217\/fmb-2015-0014","volume":"11","author":"P Tatarelli","year":"2016","unstructured":"Tatarelli P, Mikulska M. Multidrug-resistant bacteria in hematology patients: emerging threats. Future Microbiol. 2016;11:767\u201380.","journal-title":"Future Microbiol"},{"key":"2647_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/jac\/dkq494","volume":"66","author":"C Gudiol","year":"2011","unstructured":"Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, S\u00e1nchez-Ortega I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66:657\u201363.","journal-title":"J Antimicrob Chemother"},{"key":"2647_CR11","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ajh.24489","volume":"91","author":"EM Trecarichi","year":"2016","unstructured":"Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91:1076\u201381.","journal-title":"Am J Hematol"},{"key":"2647_CR12","first-page":"336","volume":"73","author":"MJ Satlin","year":"2016","unstructured":"Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Inf Secur. 2016;73:336\u201345.","journal-title":"J Inf Secur"},{"issue":"Suppl 4","key":"2647_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1046\/j.1469-0691.2001.00062.x","volume":"7","author":"J Carratal\u00e0","year":"2001","unstructured":"Carratal\u00e0 J. Role of antibiotic prophylaxis for the prevention of intravascular catheter-related infection. Clin Microbiol Infect. 2001;7(Suppl 4):83\u201390.","journal-title":"Clin Microbiol Infect"},{"key":"2647_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1469-0691.2002.00385.x","volume":"8","author":"E Bouza","year":"2002","unstructured":"Bouza E, Burillo A, Mu\u00f1oz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect. 2002;8:265\u201374.","journal-title":"Clin Microbiol Infect"},{"key":"2647_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/apm.12665","volume":"125","author":"M Gominet","year":"2017","unstructured":"Gominet M, Compain F, Beloin C, Lebeaux D. Central venous catheters and biofilms: where do we stand in 2017? APMIS. 2017;125:365\u201375.","journal-title":"APMIS"},{"key":"2647_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1046\/j.1469-0691.2002.00388.x","volume":"8","author":"J Carratal\u00e0","year":"2002","unstructured":"Carratal\u00e0 J. The antibiotic-lock technique for therapy of \u2018highly needed\u2019 infected catheters. Clin Microbiol Infect. 2002;8:282\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"2647_CR17","first-page":"343","volume":"7","author":"JA Justo","year":"2014","unstructured":"Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenge. Infect Drug Resist. 2014;7:343\u201363.","journal-title":"Infect Drug Resist"},{"key":"2647_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000360271","volume":"37","author":"H Liu","year":"2014","unstructured":"Liu H, Liu H, Deng J, Chen L, Yuan L, Wu Y. Preventing catheter-related bacteremia with taurolidine-citrate catheter locks: a systematic review and meta-analysis. Blood Purif. 2014;37:179\u201387.","journal-title":"Blood Purif"},{"key":"2647_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ijantimicag.2017.06.013","volume":"50","author":"LB Norris","year":"2017","unstructured":"Norris LB, Kablaoui F, Brilhart MK, Bookstaver PB. Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients. Int J Antimicrob Agents. 2017;50:308\u201317.","journal-title":"Int J Antimicrob Agents"},{"key":"2647_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/jac\/dkn284","volume":"62","author":"J Sanders","year":"2008","unstructured":"Sanders J, Pithie A, Ganly P, Surgenor L, Wilson R, Merriman E, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother. 2008;62:809\u201315.","journal-title":"J Antimicrob Chemother"},{"key":"2647_CR21","doi-asserted-by":"publisher","first-page":"e10840","DOI":"10.1371\/journal.pone.0010840","volume":"5","author":"L Slobbe","year":"2010","unstructured":"Slobbe L, Doorduijn JK, Lugtenburg PJ, El Barzouhi A, Boersma E, van Leeuwen WB, et al. Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS One. 2010;5:e10840.","journal-title":"PLoS One"},{"key":"2647_CR22","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.ejca.2015.06.126","volume":"51","author":"RA Schoot","year":"2015","unstructured":"Schoot RA, van Ommen CH, Stijnen T, Tissing WJ, Michiels E, Abbink FC, et al. Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: a randomised controlled multi-centre trial. Eur J Cancer. 2015;51:2031\u20138.","journal-title":"Eur J Cancer"},{"key":"2647_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.1990.8.9.1591","volume":"8","author":"C Schwartz","year":"1990","unstructured":"Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990;8:1591\u20137.","journal-title":"J Clin Oncol"},{"key":"2647_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0022-3476(95)70276-8","volume":"127","author":"WR Rackoff","year":"1995","unstructured":"Rackoff WR, Weiman M, Jakobowski D, Hirschl R, Stallings V, Bilodeau J, et al. A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. J Pediatr. 1995;127:147\u201351.","journal-title":"J Pediatr"},{"key":"2647_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/(SICI)1096-911X(199703)28:3<196::AID-MPO8>3.0.CO;2-E","volume":"28","author":"FJ Barriga","year":"1997","unstructured":"Barriga FJ, Varas M, Potin M, Sapunar F, Rojo H, Martinez A, et al. Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol. 1997;28:196\u2013200.","journal-title":"Med Pediatr Oncol"},{"key":"2647_CR26","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1128\/AAC.43.9.2200","volume":"43","author":"J Carratal\u00e0","year":"1999","unstructured":"Carratal\u00e0 J, Niub\u00f3 J, Fern\u00e1ndez-Sevilla A, Juv\u00e9 E, Castellsagu\u00e9 X, Berlanga J, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of Gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother. 1999;43:2200\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"2647_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2334-8-102","volume":"8","author":"A Simon","year":"2008","unstructured":"Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008;8:102.","journal-title":"BMC Infect Dis"},{"key":"2647_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jhin.2012.01.003","volume":"80","author":"MJ Dumichen","year":"2012","unstructured":"Dumichen MJ, Seeger K, Lode HN, K\u00fchl JS, Ebell W, Degenhardt P, et al. Randomized controlled trial of taurolidine-citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. J Hosp Infect. 2012;80:304\u20139.","journal-title":"J Hosp Infect"},{"key":"2647_CR29","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/pbc.24482","volume":"60","author":"MM Handrup","year":"2013","unstructured":"Handrup MM, Moller JK, Schroder H. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Pediatr Blood Cancer. 2013;60:1292\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"2647_CR30","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1128\/AAC.46.6.1674-1679.2002","volume":"46","author":"CB Shah","year":"2002","unstructured":"Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother. 2002;46:1674\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2647_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000470911","volume":"93","author":"R Longo","year":"2017","unstructured":"Longo R, Llorens M, Goetz C, Platini C, Eid N, Sellies J, et al. Taurolidine\/citrate lock therapy for primary prevention of catheter-related infections in cancer patients: results of a prospective, randomized, phase IV trial (ATAPAC). Oncology. 2017;93:99\u2013105.","journal-title":"Oncology"},{"key":"2647_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"},{"key":"2647_CR33","first-page":"355","volume":"97","author":"A Sitges-Serra","year":"1985","unstructured":"Sitges-Serra A, Linares J, Garau J. Catheter sepsis: the clue is the hub. Surgery. 1985;97:355\u20137.","journal-title":"Surgery"},{"key":"2647_CR34","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/JCM.33.9.2233-2239.1995","volume":"33","author":"FC Tenover","year":"1995","unstructured":"Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233\u20139.","journal-title":"J Clin Microbiol"},{"key":"2647_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.idc.2010.11.012","volume":"25","author":"DJ Weber","year":"2011","unstructured":"Weber DJ, Rutala WA. Central line-associated bloodstream infections: prevention and management. Infect Dis Clin N Am. 2011;25:77\u2013102.","journal-title":"Infect Dis Clin N Am"},{"key":"2647_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1086\/505976","volume":"43","author":"N Safdar","year":"2006","unstructured":"Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis. 2006;43:474\u201384.","journal-title":"Clin Infect Dis"},{"key":"2647_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1086\/669082","volume":"34","author":"JP Steinberg","year":"2013","unstructured":"Steinberg JP, Robichaux C, Tejedor SC, Reyes MD, Jacob JT. Distribution of pathogens in central line-associated bloodstream infections among patients with and without neutropenia following chemotherapy: evidence for a proposed modification to the current surveillance definition. Infect Control Hosp Epidemiol. 2013;34:171\u20135.","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2647-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T12:42:08Z","timestamp":1604234528000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2647-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2647"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2647-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"9 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol of the study was approved by the Research Ethics Committee at Hospital Universitari de Bellvitge (Ref. number AC019\/13) and at Hospital Virgen del Roc\u00edo (Ref. number 2017-436-1).This study will be carried out in accordance with the protocol and principles established in the latest version of the Declaration of Helsinki, with respect to the standards of Good Clinical Practice CPMP\/ICH\/135\/95, and in accordance with the Royal Decree of Clinical Trials 1090\/2015, for which the clinical trials with medicine are regulated in Spain. It incorporates in its entirety the order of the European Directive 2001\/20\/EC, relative to the provisions of the member states on the application of Good Clinical Practice in conducting clinical trials of medicine for human use.The researchers agreed, when signing the protocol, to adhere to the instructions and procedures described in them and, in this way, to follow the principles of Good Clinical Practice that they imply.The data will be treated anonymously at all times, identifying each patient with a protocol number. The privacy and confidentiality of all data will be protected. The treatment, communication, and transfer of personal data of all patients will be in accordance with the Organic Law 15\/13 December 1999.All participants will sign the informed consent. Before signing, all patients will be informed about the objectives of the study, the possible adverse reactions, the procedures to which they will be exposed, and the process of assignment of the intervention. Furthermore, they will be informed that their data will be treated with strict confidentiality.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JMC has received travel grants and honoraria as a speaker from Astellas, Novartis, Pfizer, MSD, and AstraZeneca. MA-G received honoraria as a speaker from MSD. The other authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"264"}}